A new study suggests that metformin could provide effects similar to exercise for individuals with prostate cancer

Summary:
Recent research suggests that metformin may replicate some exercise-like metabolic benefits in prostate cancer patients, particularly those undergoing hormone therapy who often face fatigue, weight gain, and reduced physical capacity. The study found that the drug increases levels of Lac-Phe, a molecule linked to appetite control and weight regulation, thereby activating pathways similar to those triggered by exercise. While this could help improve metabolic health, energy levels, and overall well-being, experts stress that metformin is not a substitute for physical activity and that more research is needed to confirm its long-term effectiveness and impact on cancer outcomes. 

Recent findings indicate that metformin may imitate certain exercise-related benefits in individuals with prostate cancer, particularly those receiving hormone therapy, which is often associated with notable metabolic shifts. This is important because many patients deal with fatigue, weight gain, and decreased endurance, making it challenging to sustain regular physical activity. By acting on key metabolic processes, the medication may help compensate for some of the limitations caused by reduced exercise.

Even though physical activity continues to be vital for overall health, these results highlight a potential option for patients who find it difficult to remain active due to their condition or treatment side effects.

The research, titled “The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients,” and published in Nature Metabolism, examines how metformin affects metabolism in those with prostate cancer.
Investigators observed that the drug increases levels of N-lactoyl-phenylalanine, or Lac-Phe, a compound usually generated during intense exercise and associated with reduced appetite and weight control.

This is particularly relevant since many prostate cancer patients—especially those undergoing hormone therapy—experience weight gain and metabolic disturbances. By raising Lac-Phe levels, metformin seems to activate pathways similar to those triggered by physical exercise.

How metformin mimics exercise

A key focus of the study is Lac-Phe, a molecule gaining recognition for its role in exercise-related biology. Higher levels of Lac-Phe in the body may:

• Decrease appetite and food consumption
• Aid in managing body weight
• Enhance metabolic function

Dr Vineet Malhotra, Senior Urologist at SCM Healthcare, Delhi, explains that metformin increases Lac-Phe, a molecule typically produced during vigorous physical activity. He notes that this compound can help reduce hunger and support weight loss, which is especially beneficial for prostate cancer patients receiving hormone therapy.

He further adds that these metabolic effects may help patients maintain better energy levels and stability during treatment, which can be physically demanding.

Why this matters for prostate cancer patients

Treatment for prostate cancer, particularly androgen deprivation therapy, often leads to fatigue, weight gain, and reduced strength. These side effects can make it difficult to engage in regular exercise, even though it is strongly advised.
In such cases, metformin may serve as a supportive aid.

Dr Malhotra explains that the drug can assist patients who are unable to exercise due to illness or exhaustion, helping them feel better and more energetic. However, he emphasizes that it is not a substitute for exercise, which provides broader benefits, while metformin can only replicate some aspects.

Potential benefits highlighted by the study

The findings suggest several encouraging outcomes, particularly in enhancing quality of life:

• Assists in weight control during hormone therapy
• Promotes improved metabolic health
• May boost energy levels and overall well-being

These advantages could be especially important in long-term cancer care, where maintaining both physical and metabolic health is essential.

Key limitations to keep in mind

Despite promising results, experts advise caution, as the research is still in its early stages and several uncertainties remain:

• It is not yet clear whether metformin improves long-term survival in prostate cancer patients
• Its sustained impact on quality of life remains uncertain
• Additional clinical trials are required to confirm safety and effectiveness for this group

As Dr Malhotra points out, there is still a gap between improvements in metabolism and actual cancer-related outcomes.

Although the study draws interesting comparisons between metformin and exercise, it does not reduce the importance of staying physically active. Exercise supports multiple systems in the body, including heart health, muscle strength, and mental well-being. In contrast, metformin appears to replicate only a limited portion of these benefits, mainly those related to metabolism and appetite.

This distinction is important for both patients and healthcare providers when considering treatment strategies.

While the possibility that a widely used diabetes medication could aid in cancer care is intriguing, further research is needed before metformin can be routinely included in prostate cancer treatment. Future studies must address key questions around long-term effects, appropriate dosing, and which patients are most likely to benefit. Until then, metformin should be considered a complementary approach rather than a replacement for established lifestyle practices.